Literature DB >> 11533901

Global "burden of disease"-study for psychiatric disorders.

T B Ustün1, D Chisholm.   

Abstract

The Global Burden of Disease (GBD) study was conducted to provide a set of summary health measures that would be comprehensive and make available information on disease and injury, including non-fatal health outcomes. The main objective of the GBD approach was to inform global priority setting for health research and to influence international health policy and planning. One of the summary measures used was the Disability Adjusted Life Year (DALY). DALYs are a common metric for fatal and non-fatal health outcomes and are based on years of life lost because of premature death (YLL) and years of life lived with disability (YLD). Thus DALYs = YLL + YLD or Burden = Mortality + Disability. Therefore, a DALY is one lost year of healthy life. The DALY methodology provides a way to link information on disease burden to cost-effectiveness analysis. This feature would assist comparative assessments. The WHO plans to refine this framework for assessing the outcomes of interventions and their related costs.

Entities:  

Mesh:

Year:  2001        PMID: 11533901     DOI: 10.1055/s-2001-15381

Source DB:  PubMed          Journal:  Psychiatr Prax        ISSN: 0303-4259


  6 in total

Review 1.  Gene expression profiling with DNA microarrays: advancing our understanding of psychiatric disorders.

Authors:  Julie Pongrac; Frank A Middleton; David A Lewis; Pat Levitt; Károly Mirnics
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

2.  Long-Term Clinical Outcomes from a Randomized Controlled Trial of Two Implementation Strategies to Promote Collaborative Care Attendance in Community Practices.

Authors:  Amy M Kilbourne; David E Goodrich; Kristina M Nord; Celeste Van Poppelen; Julia Kyle; Mark S Bauer; Jeanette A Waxmonsky; Zongshan Lai; Hyungjin M Kim; Daniel Eisenberg; Marshall R Thomas
Journal:  Adm Policy Ment Health       Date:  2015-09

3.  Life Goals Collaborative Care for patients with bipolar disorder and cardiovascular disease risk.

Authors:  Amy M Kilbourne; David E Goodrich; Zongshan Lai; Julia Clogston; Jeanette Waxmonsky; Mark S Bauer
Journal:  Psychiatr Serv       Date:  2012-12       Impact factor: 3.084

4.  Randomized controlled trial to assess reduction of cardiovascular disease risk in patients with bipolar disorder: the Self-Management Addressing Heart Risk Trial (SMAHRT).

Authors:  Amy M Kilbourne; David E Goodrich; Zongshan Lai; Edward P Post; Karen Schumacher; Kristina M Nord; Margretta Bramlet; Stephen Chermack; David Bialy; Mark S Bauer
Journal:  J Clin Psychiatry       Date:  2013-07       Impact factor: 4.384

5.  Randomised trials relevant to mental health conducted in low and middle-income countries: protocol for a survey of studies published in 1991, 1995 and 2000 and assessment of their relevance.

Authors:  Rebecca J Syed Sheriff; Mahesh Jayaram; Prathap Tharyan; Lelia Duley; Clive E Adams
Journal:  BMC Psychiatry       Date:  2006-09-26       Impact factor: 3.630

6.  Protocol: Adaptive Implementation of Effective Programs Trial (ADEPT): cluster randomized SMART trial comparing a standard versus enhanced implementation strategy to improve outcomes of a mood disorders program.

Authors:  Amy M Kilbourne; Daniel Almirall; Daniel Eisenberg; Jeanette Waxmonsky; David E Goodrich; John C Fortney; JoAnn E Kirchner; Leif I Solberg; Deborah Main; Mark S Bauer; Julia Kyle; Susan A Murphy; Kristina M Nord; Marshall R Thomas
Journal:  Implement Sci       Date:  2014-09-30       Impact factor: 7.327

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.